134 related articles for article (PubMed ID: 10566146)
1. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions.
Biragyn A; Kwak LW
Immunol Rev; 1999 Aug; 170():115-26. PubMed ID: 10566146
[TBL] [Abstract][Full Text] [Related]
2. Translational development of active immunotherapy for hematologic malignancies.
Kwak LW
Int J Hematol; 2002 Aug; 76 Suppl 1():320-1. PubMed ID: 12430873
[TBL] [Abstract][Full Text] [Related]
3. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens.
Biragyn A; Surenhu M; Yang D; Ruffini PA; Haines BA; Klyushnenkova E; Oppenheim JJ; Kwak LW
J Immunol; 2001 Dec; 167(11):6644-53. PubMed ID: 11714836
[TBL] [Abstract][Full Text] [Related]
4. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity.
Biragyn A; Schiavo R; Olkhanud P; Sumitomo K; King A; McCain M; Indig FE; Almanzar G; Baatar D
J Immunol; 2007 Jul; 179(2):1381-8. PubMed ID: 17617631
[TBL] [Abstract][Full Text] [Related]
6. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity.
Biragyn A; Tani K; Grimm MC; Weeks S; Kwak LW
Nat Biotechnol; 1999 Mar; 17(3):253-8. PubMed ID: 10096292
[TBL] [Abstract][Full Text] [Related]
7. DNA fusion vaccines against B-cell tumors.
Zhu D; Rice J; Savelyeva N; Stevenson FK
Trends Mol Med; 2001 Dec; 7(12):566-72. PubMed ID: 11733220
[TBL] [Abstract][Full Text] [Related]
8. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis.
Ruffini PA; Biragyn A; Coscia M; Harvey LK; Cha SC; Bogen B; Kwak LW
J Leukoc Biol; 2004 Jul; 76(1):77-85. PubMed ID: 15075363
[TBL] [Abstract][Full Text] [Related]
9. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
11. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.
Pai Kasturi S; Qin H; Thomson KS; El-Bereir S; Cha SC; Neelapu S; Kwak LW; Roy K
J Control Release; 2006 Jul; 113(3):261-70. PubMed ID: 16793161
[TBL] [Abstract][Full Text] [Related]
13. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences.
Fredriksen AB; Bogen B
Blood; 2007 Sep; 110(6):1797-805. PubMed ID: 17540847
[TBL] [Abstract][Full Text] [Related]
14. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.
Singh A; Qin H; Fernandez I; Wei J; Lin J; Kwak LW; Roy K
J Control Release; 2011 Oct; 155(2):184-92. PubMed ID: 21708196
[TBL] [Abstract][Full Text] [Related]
15. [Construction of expression plasmid for fused idiotypic DNA vaccine of B-cell lymphoma].
Wang FX; Zhang Y; Zhao B; Pan L; Zhang XJ; Luo JM; Dong ZR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1453-8. PubMed ID: 20030925
[TBL] [Abstract][Full Text] [Related]
16. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
Fredriksen AB; Sandlie I; Bogen B
Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
[TBL] [Abstract][Full Text] [Related]
17. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
18. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
19. [The experimental study on idiotypic DNA vaccine against human B-cell lymphoma to induce antitumor immune response].
Zhong KL; Zhang WJ; Yuan Y; Wu Y; Zhang MW; Mao N
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):609-15. PubMed ID: 14706145
[TBL] [Abstract][Full Text] [Related]
20. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity.
Qin H; Cha SC; Neelapu SS; Lou Y; Wei J; Liu YJ; Kwak LW
Blood; 2009 Nov; 114(19):4142-9. PubMed ID: 19749091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
